Barinthus Biotherapeutics plc (NASDAQ:BRNS) Sees Significant Decline in Short Interest

Barinthus Biotherapeutics plc (NASDAQ:BRNS) was the recipient of a large drop in short interest in the month of July. As of July 31st, there was short interest totalling 14,800 shares, a drop of 50.3% from the July 15th total of 29,800 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 22,900 shares, the short-interest ratio is presently 0.6 days.

Barinthus Biotherapeutics Stock Down 0.4 %

BRNS traded down $0.00 during trading on Wednesday, reaching $1.32. 4,365 shares of the stock traded hands, compared to its average volume of 20,976. The stock’s 50-day moving average is $1.51 and its 200 day moving average is $2.18. Barinthus Biotherapeutics has a 12 month low of $1.21 and a 12 month high of $5.10. The stock has a market capitalization of $51.52 million, a PE ratio of -0.75 and a beta of -0.52.

Barinthus Biotherapeutics (NASDAQ:BRNS) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.01). As a group, equities research analysts anticipate that Barinthus Biotherapeutics will post -1.9 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have weighed in on BRNS shares. HC Wainwright reiterated a “buy” rating and issued a $5.00 price objective on shares of Barinthus Biotherapeutics in a research note on Monday. Alliance Global Partners cut their price objective on shares of Barinthus Biotherapeutics from $11.00 to $9.50 and set a “buy” rating for the company in a research report on Tuesday. William Blair reiterated an “outperform” rating on shares of Barinthus Biotherapeutics in a research note on Thursday, June 13th. Finally, Barclays decreased their target price on Barinthus Biotherapeutics from $7.00 to $3.00 and set an “overweight” rating on the stock in a research report on Thursday, June 13th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Catalina Capital Group LLC acquired a new position in shares of Barinthus Biotherapeutics during the second quarter valued at about $25,000. Ipswich Investment Management Co. Inc. bought a new stake in Barinthus Biotherapeutics in the 2nd quarter valued at about $32,000. BlueCrest Capital Management Ltd acquired a new position in Barinthus Biotherapeutics during the 1st quarter worth approximately $1,292,000. DC Funds LP bought a new position in Barinthus Biotherapeutics in the first quarter worth approximately $1,528,000. Finally, Alphabet Inc. acquired a new stake in Barinthus Biotherapeutics in the second quarter valued at approximately $2,119,000. 25.20% of the stock is owned by institutional investors.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.